Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.48 (26.812%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 21st Oct 2014 08:50

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating.Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy recommendation.Antofagasta: JP Morgan reduces target price from 830p to 760p maintaining a neutral rating.BHP Billiton: JP Morgan reduces target price from 2250p to 2180p keeping a neutral rating.Brooks Macdonald: Numis reduces target price from 1550p to 1470p retaining its hold recommendation.Brown (N) Group: Credit Suisse reduces target price from 518p to 330p downgrading to neutral.BT Group: Goldman Sachs cuts target price from 620p to 600p retaining a strong buy recommendation.Cable & Wireless Communications: JP Morgan lowers target price from 53p to 50p and maintains a neutral rating.Dairy Crest: UBS cuts target price from 460p to 410p retaining a neutral rating.Devro: N+1 Singer upgrades from hold to buy with a target price of 257p.Dialight: Investec upgrades from sell to hold with a target price of 850p.GKN: JP Morgan reduces target price from 460p to 370p reiterating its overweight rating.Go Ahead Group: Investec increases target price from 2670p to 2750p and leaves its buy recommendation unchanged.Hellermann Tyton: UBS initiates with a target price of 300p and a neutral rating.Hochschild Mining: JP Morgan cuts target price from 185p to 150p keeping its neutral rating.Informa: Westhouse Securities upgrades from neutral to buy with a target price of 554p.Inmarsat: JP Morgan ups target price from 810p to 840p and reiterates an overweight rating.Kazakhmys: JP Morgan cuts target price from 400p to 375p and stays with its overweight rating.Lloyds Banking Group: Credit Suisse shifts target price from 68p to 72p and stays with its neutral rating.NMC Health: Investec initiates with a target price of 610p and a buy recommendation.Petropavlovsk: JP Morgan lowers target price from 20p to 10p and reiterates an underweight rating.President Energy: Canaccord Genuity moves target price from 50p to 60p and retains its speculative buy recommendation.Redefine: Deutsche Bank lowers target price from 56p to 53p keeping its hold recommendation.Rightmove: Credit Suisse reduces target price from 3100p to 2655p and reiterates an outperform rating.Standard Chartered: Credit Suisse reduces target price from 1150p to 1020p and maintains an underperform rating.Synairgen: N+1 Singer initiates with a target price of 49p and a buy recommendation.Talk Talk Telecom: Goldman Sachs cuts target price from 450p to 435p and maintains a buy recommendation.Telecity Group: JP Morgan ups target price from 900p to 925p and keeps an overweight rating.Travis Perkins: UBS reduces target price from 2100p to 2000p reiterating a buy recommendation. Deutsche Bank lowers target price from 1901p to 1898p and keeps its hold recommendation.Vedanta Resources: JP Morgan reduces target price from 1130p to 1030p and retains a neutral rating.William Hill: Canaccord Genuity moves target price from 350p to 365p and keeps a hold recommendation.Zoopla Property: Credit Suisse cuts target price from 290p to 270p leaving its outperform rating unaltered.
More News
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.